📈 Rock-Solid Dividend Stocks

Advertise with us | Our Newsletters | Your Rewards

Good Morning!

This week, Wall Street's bouncing back thanks to the Bank of Japan, and all eyes are on Walt Disney's earnings. Super Micro took a hit with a 13% drop after missing earnings expectations, but Workiva's down 54%—a prime dip-buying opportunity according to Wall Street.

In our top stories, we dive into why Merck and Medtronic are rock-solid dividend picks. Merck's got a booming product pipeline and impressive dividend growth, while Medtronic shines with its diverse portfolio and near-Dividend King status.

Grab your coffee and let's get into it! ☕️👇️

Steal our best value stock ideas.

PayPal, Disney, and Nike all dropped 50-80% recently from all-time highs.

Are they undervalued? Can they turn around? What’s next? You don’t have time to track every stock, but should you be forced to miss all the best opportunities?

That’s why we scour hundreds of value stock ideas for you. Whenever we find something interesting, we send it straight to your inbox.

Subscribe free to Value Investor Daily with one click so you never miss out on our research again.

From our partners

Markets

📈 Futures rebound, Walt Disney, BOJ - what's moving markets
Wall Street is bouncing back after Monday's sharp drop, with a boost from the Bank of Japan ruling out more rate hikes. Focus is now on Walt Disney's earnings amid the ongoing global earnings season.

📉 Super Micro Shares Sink 13% on Big Earnings Miss, 10-for-1 Stock Split
Super Micro Computer's (SMCI) stock took a nosedive, dropping 13% in pre-market trading after disappointing earnings. They posted $6.25 a share, missing the $8.07 expected, and saw an 11.2% drop in gross margin. Revenue slightly beat expectations at $5.31 billion.

🤑1 Growth Stock Down 54% to Buy on the Dip, According to Wall Street
Workiva's (WK) cloud-based software suite is gaining traction, especially in the ESG space. With its stock at a four-year low, Wall Street is optimistic about its future.

BUSINESS

Rock-Solid Dividend Stocks: Merck and Medtronic

The Case for Merck: A Leader in Pharmaceuticals

Merck, a titan in the pharmaceutical industry, is a compelling choice for long-term investors. The company is renowned for its consistent innovation and robust product pipeline. Here’s why Merck stands out:

• Resilient Demand: Drug companies have a unique advantage – their products are always in demand. Patients need their medications regardless of economic conditions, ensuring a steady revenue stream.

• Top-Selling Drug: Merck's flagship product, Keytruda, is the world’s best-selling drug. While it faces patent expiration in 2028, Merck is already preparing with innovative successors like Winrevair, which treats pulmonary arterial hypertension and has significant sales potential.

• Strong Pipeline: Merck boasts over 80 programs in phase 2 trials and more than 30 in phase 3, indicating a future filled with new, revenue-generating products. This depth in research and development underpins its long-term growth strategy.

Dividend Strength: Over the past decade, Merck has increased its dividend payouts by 75%, currently offering a forward yield of 2.7%, significantly higher than the S&P 500 average of 1.3%. This robust financial health ensures sustained dividend growth, making Merck a top pick for income-focused investors.

Check out Merck's stock performance for more insights.

Medtronic: A Steady Performer in Medical Devices

Medtronic, a leader in the medical device sector, offers stability and growth potential. With a diverse product portfolio and a strong presence in several high-demand medical segments, Medtronic is well-positioned for the future. Here’s what makes Medtronic a reliable investment:

• Diverse Portfolio: Medtronic’s products span across diabetes care, cardiovascular, medical surgical, and neuroscience segments, providing a balanced revenue base.

• Innovation in AI and Robotics: The company is integrating artificial intelligence to enhance product efficiency and is poised to challenge competitors in the robotic-assisted surgery market with its Hugo robot, currently undergoing testing for U.S. clearance.

• Demographic Trends: The aging global population will continue to drive demand for Medtronic’s medical devices, ensuring steady growth opportunities.

Dividend Reliability: Medtronic has increased its dividends for 47 consecutive years, approaching the prestigious Dividend King status. Its forward yield of around 3.5% is a testament to its consistent and reliable performance, making it a solid choice for dividend investors.

For a closer look at Medtronic's market trends, visit Medtronic's stock chart.

Conclusion: Why These Stocks Are Long-Term Winners

Both Merck and Medtronic exemplify the qualities of reliable dividend stocks: robust business models, consistent innovation, and strong financial health. They are prime candidates for investors looking to secure steady, long-term returns.

• Merck: Leading in pharmaceuticals with a strong pipeline and impressive dividend growth.

• Medtronic: Dominant in medical devices with a diverse product range and a remarkable dividend track record.

Incorporating these stocks into your portfolio could provide not just financial stability but also potential for growth, making them indispensable assets for any long-term investor.

Credit: The Motley Fool

Our Recommendations:

💻️ MEXC - Where we find and trade Crypto with low fees.
📈 TradingView - Software we use to chart stocks.
🔐 Trezor - Our favorite hardware wallet to keep our Crypto secure.
🦑 Kraken - Where we buy crypto with cash / withdraw profit to our bank.

Thanks for reading, if you enjoyed, tell your friends!

P.S: If you're interested in crypto and web3 - check out our new newsletter, The Crypto Journal!

Share The Investing Journal with your friends to receive rewards!